Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation
Jingyan Tang,Jie Yu,Jiaoyang Cai,Li Zhang,Shaoyan Hu,Ju Gao,Hua Jiang,Yongjun Fang,Changda Liang,Xiuli Ju,Runming Jin,Xiaowen Zhai,Xuedong Wu,Xin Tian,Qun Hu,Ningling Wang,Hui Jiang,Lirong Sun,Alex W K Leung,Minghua Yang,Kaili Pan,Cheng Cheng,Yiping Zhu,Hui Zhang,Chunfu Li,Jun J Yang,Chi-Kong Li,Xiaofan Zhu,Shuhong Shen,Ching-Hon Pui,Alex W. K. Leung,Jun J. Yang,Chi-kong Li
DOI: https://doi.org/10.1182/blood.2020010438
IF: 20.3
2021-03-08
Blood
Abstract:Abstract To identify the prognostic factors that are useful to improve central nervous system (CNS) control in children with acute lymphoblastic leukemia (ALL), we analyzed the outcome of 7640 consecutive patients treated on Chinese Children’s Cancer Group ALL-2015 protocol between 2015 and 2019. This protocol featured prephase dexamethasone treatment before conventional remission induction and subsequent risk-directed therapy, including 16 to 22 triple intrathecal treatments, without prophylactic cranial irradiation. The 5-year event-free survival was 80.3% (95% confidence interval [CI], 78.9-81.7), and overall survival 91.1% (95% CI, 90.1-92.1). The cumulative risk of isolated CNS relapse was 1.9% (95% CI, 1.5-2.3), and any CNS relapse 2.7% (95% CI, 2.2-3.2). The isolated CNS relapse rate was significantly lower in patients with B-cell ALL (B-ALL) than in those with T-cell ALL (T-ALL) (1.6%; 95% CI, 1.2-2.0 vs 4.6%; 95% CI, 2.9-6.3; P < .001). Independent risk factors for isolated CNS relapse included male sex (hazard ratio [HR], 1.8; 95% CI, 1.1-3.0; P = .03), the presence of BCR-ABL1 fusion (HR, 3.8; 95% CI, 2.0-7.3; P < .001) in B-ALL, and presenting leukocyte count ≥50×109/L (HR, 4.3; 95% CI, 1.5-12.2; P = .007) in T-ALL. Significantly lower isolated CNS relapse was associated with the use of total intravenous anesthesia during intrathecal therapy (HR, 0.2; 95% CI, 0.04-0.7; P = .02) and flow cytometry examination of diagnostic cerebrospinal fluid (CSF) (HR, 0.2; 95% CI, 0.06-0.6; P = .006) among patients with B-ALL. Prephase dexamethasone treatment, delayed intrathecal therapy, use of total intravenous anesthesia during intrathecal therapy, and flow cytometry examination of diagnostic CSF may improve CNS control in childhood ALL. This trial was registered with the Chinese Clinical Trial Registry (ChiCTR-IPR-14005706).
hematology